Ticari basın bülteni
FDA acquires GEA ConsiGma 1 unit for their CDER/OPQ Continuous Lab
02 Feb 2018
The FDA has purchased a GEA ConsiGma™ 1 OSD development unit, which is housed in the CDER/OPQ (Office of Pharmaceutical Quality). The GEA ConsiGma™ 1 will be an important asset for continuous manufacturing research within the OPQ Office of Testing and Research and Emerging Technologies Team.
The FDA/CDER/OPQ mission is to ensure that safe, effective, high quality drugs are available for the American public. Established in 2015, OPQ encourages and supports development and adoption of emerging technology to modernize pharmaceutical development and manufacturing.
In development, scientist and engineers need to investigate the capability of their processes and develop strategies to avoid or manage the effects variability from various sources. The GEA ConsiGma™ 1 enables development of granules following QbD principles via fast DOE approaches with controlled continuous operation, providing an opportunity to explore a wider range of process parameters with less product and less time. The result is much better process understanding in a shorter time and with lower costs.
Media Relations
GEA Group Aktiengesellschaft
Peter-Müller-Str. 12
40468
Düsseldorf
Germany
+49 211 9136-0
GEA Hakkında
GEA, 2019 yılında 4,9 milyar EUR konsolide geliri ile gıda işleme endüstrisi ve diğer birçok endüstri için en büyük tedarikçilerden birisidir.
